Voluntary and Business Update Announcement Approval of Drug Clinical Trials for Systemic Lupus Erythematosus of Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001
Filed with HKEX · Stock code 867 ·
6ix hasn’t read this filing yet.
China Medical System Holdings Ltd. on 6ix
Earlier from China Medical System
- CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China
- CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
- CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions
- CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®
- CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
Later from China Medical System
- Change of company name of Singapore share transfer agent
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow China Medical System into a list and get an email when it puts out news.
Follow China Medical System